Sheela Ann Abraham

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9151004/publications.pdf

Version: 2024-02-01

26 papers	1,638 citations	567281 15 h-index	713466 21 g-index
28 all docs	28 docs citations	28 times ranked	2611 citing authors

#	Article	IF	Citations
1	Extracellular vesicles tell all: How vesicle-mediated cellular communication shapes hematopoietic stem cell biology with increasing age. Experimental Hematology, 2021, 101-102, 7-15.	0.4	5
2	BRD4-mediated repression of p53 is a target for combination therapy in AML. Nature Communications, 2021, 12, 241.	12.8	43
3	Blood extracellular vesicles from healthy individuals regulate hematopoietic stem cells as humans age. Aging Cell, 2020, 19, e13245.	6.7	12
4	3102 â€“ A SYNTHETIC LETHALITY APPROACH TO ERADICATE AML VIA SYNERGISTIC ACTIVATION OF PRO-APOPTOTIC P53 BY MDM2 AND BET INHIBITORS. Experimental Hematology, 2020, 88, S70.	0.4	0
5	A Synthetic Lethal Approach to Eradicate AML Via Synergistic Activation of Pro-Apoptotic p53 By MDM2 and BET Inhibitors. Blood, 2020, 136, 14-14.	1.4	0
6	hsa-mir183/EGR1â€“mediated regulation of E2F1 is required for CML stem/progenitor cell survival. Blood, 2018, 131, 1532-1544.	1.4	40
7	Validating a network hub in leukaemia stem cells. Oncoscience, 2017, 4, 3-4.	2.2	0
8	Casting a NETwork instead of shooting magic bullets. Cell Cycle, 2016, 15, 3147-3148.	2.6	0
9	Biological Analysis of Human CML Stem Cells; Xenograft Model of Chronic Phase Human Chronic Myeloid Leukemia. Methods in Molecular Biology, 2016, 1465, 175-185.	0.9	2
10	CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells. Blood, 2016, 128, 371-383.	1.4	61
11	Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature, 2016, 534, 341-346.	27.8	204
12	Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival. Journal of Clinical Investigation, 2014, 124, 3847-3862.	8.2	53
13	Quantitative proteomics analysis of <scp>BMS</scp>â€214662 effects on <scp>CD</scp>34 positive cells from chronic myeloid leukaemia patients. Proteomics, 2013, 13, 153-168.	2.2	6
14	A pathway from leukemogenic oncogenes and stem cell chemokines to RNA processing via THOC5. Leukemia, 2013, 27, 932-940.	7.2	23
15	A Specific PTPRC/CD45 Phosphorylation Event Governed by Stem Cell Chemokine CXCL12 Regulates Primitive Hematopoietic Cell Motility. Molecular and Cellular Proteomics, 2013, 12, 3319-3329.	3.8	18
16	Redirecting traffic using the XPO1 police. Blood, 2013, 122, 2926-2928.	1.4	13
17	p53 and c-Myc Are Critical Signaling Hubs That Maintain Chronic Myeloid Leukemia. Blood, 2013, 122, 1465-1465.	1.4	0
18	Hurdles Toward a Cure for CML: The CML Stem Cell. Hematology/Oncology Clinics of North America, 2011, 25, 951-966.	2.2	23

#	Article	IF	Citations
19	Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magnetic Resonance in Medicine, 2006, 56, 1011-1018.	3.0	119
20	Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. Journal of Controlled Release, 2005, 104, 271-288.	9.9	108
21	The Liposomal Formulation of Doxorubicin. Methods in Enzymology, 2005, 391, 71-97.	1.0	332
22	In Vitro and in Vivo Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading. Clinical Cancer Research, 2004, 10, 728-738.	7.0	95
23	An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. Journal of Controlled Release, 2004, 96, 449-461.	9.9	94
24	In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: Illustration of targeted delivery. Magnetic Resonance in Medicine, 2004, 51, 1153-1162.	3.0	176
25	Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1561, 188-201.	2.6	60
26	Formation of transition metalâ€“doxorubicin complexes inside liposomes. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1565, 41-54.	2.6	150